Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 6 trials

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

5Total
Not Applicable (1)
P 1 (1)
P 2 (1)
P 3 (2)

Trial Status

Recruiting5
Withdrawn1

Clinical Trials (6)

Showing 6 of 6 trials
NCT07443306Phase 2RecruitingPrimary

A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Medium to High Risk Myelofibrosis

NCT07317700Phase 3RecruitingPrimary

A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis

NCT07362225Recruiting

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

NCT04686682Phase 1Recruiting

A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors

NCT06479135Phase 3Recruiting

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

NCT02469974Not ApplicableWithdrawn

Ruxolitinib in Combination With Autotransplant

Showing all 6 trials

Research Network

Activity Timeline